Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 15, 2012VirulenceOpen Access

The ebolavirus VP24 interferon antagonist

View Full Paper
Ask AI
Bookmark
Share

Authors

AZAdrianna P. P. ZhangDADafna M. AbelsonMapp Biopharmaceutical (United States)ZBZachary A. BornholdtMapp Biopharmaceutical (United States)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Zhang et al. (2012) studied this question.

synapsesocial.com/papers/6aa9332a1ed6af7fb80e082bhttps://doi.org/10.4161/viru.21302
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ebolavirus VP35 suppresses IFN production from conventional but not plasmacytoid dendritic cells2011 · 57 citations
  2. 2Ebola Virus VP24 Binds Karyopherin α1 and Blocks STAT1 Nuclear Accumulation2006 · 461 citations
  3. 3<i>Ebolavirus</i> VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression2009 · 132 citations
  4. 4VP24 of Marburg Virus Influences Formation of Infectious Particles2005 · 94 citations
  5. 5Regions in Ebola Virus VP24 That Are Important for Nucleocapsid Formation2007 · 58 citations